ARVINAS, INC. Revenue from Contract with Customer, Excluding Assessed Tax
ARVINAS, INC. (ARVN) reported Revenue from Contract with Customer, Excluding Assessed Tax of $249.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- ARVINAS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $249.70M, a 1014.73% increase year-over-year.
- ARVINAS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $15.60M, a 91.74% decline year-over-year.
- ARVINAS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $22.40M.
- ARVINAS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $188.80M.
- ARVINAS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $46.70M, a 114.22% increase from fiscal 2020.
- ARVINAS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $21.80M, a 19.13% increase from fiscal 2019.
- ARVINAS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $18.30M, a 27.97% increase from fiscal 2018.
- ARVINAS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2018 was $14.30M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $249.70M 10-Q · filed 2026-08-04 | $265.30M 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | $15.60M 10-Q · filed 2026-05-11 | |||
| 2025-06-30 | $22.40M 10-Q · filed 2026-08-04 | $211.20M 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | $188.80M 10-Q · filed 2026-05-11 | |||
| 2021-12-31 | $26.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $35.60M derived: sum of 2 quarters · filed 2022-02-28 | $41.20M derived: sum of 3 quarters · filed 2022-02-28 | $46.70M 10-K · filed 2022-02-28 |
| 2021-09-30 | $9.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $14.80M derived: sum of 2 quarters · filed 2021-11-03 | $20.30M 10-Q · filed 2021-11-03 | $22.60M derived: sum of 4 quarters · filed 2021-11-03 |
| 2021-06-30 | $5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $11.10M 10-Q · filed 2021-08-05 | $13.40M derived: sum of 3 quarters · filed 2021-08-05 | $20.90M derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | $5.50M 10-Q · filed 2021-05-04 | $7.80M derived: sum of 2 quarters · filed 2021-05-04 | $15.30M derived: sum of 3 quarters · filed 2021-05-04 | $21.10M derived: sum of 4 quarters · filed 2021-05-04 |
| 2020-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $9.80M derived: sum of 2 quarters · filed 2021-03-01 | $15.60M derived: sum of 3 quarters · filed 2021-03-01 | $21.80M 10-K · filed 2021-03-01 |
| 2020-09-30 | $7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $13.30M derived: sum of 2 quarters · filed 2020-11-05 | $19.50M 10-Q · filed 2020-11-05 | $24.40M derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | $5.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $12.00M 10-Q · filed 2020-08-04 | $16.90M derived: sum of 3 quarters · filed 2020-08-04 | $22.30M derived: sum of 4 quarters · filed 2020-08-04 |
| 2020-03-31 | $6.20M 10-Q · filed 2020-04-28 | $11.10M derived: sum of 2 quarters · filed 2020-04-28 | $16.50M derived: sum of 3 quarters · filed 2020-04-28 | $20.50M derived: sum of 4 quarters · filed 2020-04-28 |
| 2019-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $10.30M derived: sum of 2 quarters · filed 2020-03-16 | $14.30M derived: sum of 3 quarters · filed 2020-03-16 | $18.30M 10-K · filed 2020-03-16 |
| 2019-09-30 | $5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $9.40M derived: sum of 2 quarters · filed 2019-11-04 | $13.40M 10-Q · filed 2019-11-04 | $16.80M derived: sum of 4 quarters · filed 2019-11-04 |
| 2019-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $8.00M 10-Q · filed 2019-08-05 | $11.40M derived: sum of 3 quarters · filed 2019-08-05 | |
| 2019-03-31 | $4.00M 10-Q · filed 2019-05-09 | $7.40M derived: sum of 2 quarters · filed 2019-05-09 | ||
| 2018-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $14.30M 10-K · filed 2019-03-26 | ||
| 2018-09-30 | $10.90M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |